← Leaderboards
Takashi Tsukamoto
Johns Hopkins University
$11,312,957
Attributed
$17,969,057
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,969,057 · 12
By mechanism
R01$10,358,203 · 4
R61$2,377,324 · 3
UH3$2,299,466 · 1
UG3$1,583,144 · 1
R21$941,584 · 2
R33$409,336 · 1
Top collaborators
- Barbara Stauch Slusher18 shared
- Amy F.T. Arnsten5 shared
- Rana Rais3 shared
- Camilo Rojas2 shared
- Michael A Koldobskiy1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Barbara Stauch Slusher$18,499,514
- Linda J Van Eldik$37,023,709
- Philip A Cole$22,629,551
- Rana Rais$2,718,642
- Lawrence M Szewczuk$63,153
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposIn VivoIn VitroDrug KineticsDrug DiscoveryBrainExhibitsDoseCognitive DeficitsPre-ClinicalPharmaceutical PreparationsLeadMolecularMouse ModelEnzymesResearch PersonnelAnalogGeneticPreventStructure-Activity RelationshipPlayOralCellsBase
Grant awards (30)
Development of brain-penetrant, histone evicting anthracycline drugs for treatment of diffuse midline glioma$773,607
R61 · FY2025 · NS
Development of neutral sphingomyelinase 2 (nSMase2) inhibitors for the treatment of Alzheimer's disease$710,695
R01 · FY2025 · AG · contact PI
Development of NAT8L inhibitors for the Treatment of Canavan Disease$393,942
R61 · FY2025 · NS · contact PI
Development of GCPII inhibitors for the treatment of age-related cognitive disorders$784,969
R01 · FY2024 · AG · contact PI
Development of neutral sphingomyelinase 2 (nSMase2) inhibitors for the treatment of Alzheimer's disease$683,930
R01 · FY2024 · AG · contact PI
Development of NAT8L inhibitors for the Treatment of Canavan Disease$396,324
R61 · FY2024 · NS · contact PI
Development of GCPII inhibitors for the treatment of age-related cognitive disorders$784,616
R01 · FY2023 · AG · contact PI
Development of MRGPRX1 positive allosteric modulators as non-addictive therapies for neuropathic pain$774,484
UH3 · FY2023 · NS · contact PI
Development of neutral sphingomyelinase 2 (nSMase2) inhibitors for the treatment of Alzheimer's disease$651,180
R01 · FY2023 · AG · contact PI
High Throughput Screen for Discovery of N-Acetyltransferase 8 Like (NAT8L) Inhibitors$409,336
R33 · FY2023 · NS
Development of GCPII inhibitors for the treatment of age-related cognitive disorders$828,290
R01 · FY2022 · AG · contact PI
High throughput screen for discovery of N-acetyltransferase 8 Like (NAT8L) inhibitors$404,097
R61 · FY2022 · NS
Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's Disease$401,436
R01 · FY2022 · AG
Development of MRGPRX1 positive allosteric modulators as non-addictive therapies for neuropathic pain$1,524,982
UH3 · FY2021 · NS · contact PI
Development of GCPII inhibitors for the treatment of age-related cognitive disorders$704,994
R01 · FY2021 · AG · contact PI
Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's Disease$492,421
R01 · FY2021 · AG
High throughput screen for discovery of N-acetyltransferase 8 Like (NAT8L) inhibitors$409,354
R61 · FY2021 · NS
Development of GCPII inhibitors for the treatment of age-related cognitive disorders$720,931
R01 · FY2020 · AG · contact PI
Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's Disease$492,421
R01 · FY2020 · AG
Development of MRGPRX1 positive allosteric modulators as non-addictive therapies for neuropathic pain$1,583,144
UG3 · FY2019 · NS · contact PI
Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's Disease$492,421
R01 · FY2019 · AG
Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's Disease$492,421
R01 · FY2018 · AG
Positive allosteric modulators of MrgX1 for the treatment of chronic pain$245,469
R21 · FY2018 · NS · contact PI
Positive allosteric modulators of MrgX1 for the treatment of chronic pain$204,115
R21 · FY2017 · NS · contact PI
DAAO Inhibitors for the treatment of Schizophrenia$366,784
R01 · FY2014 · MH · contact PI
DAAO Inhibitors for the treatment of Schizophrenia$572,322
R01 · FY2013 · MH · contact PI
DAAO Inhibitors for the treatment of Schizophrenia$585,206
R01 · FY2012 · MH · contact PI
Novel Therapeutic Agents for Gliomas with IDH Mutations$246,000
R21 · FY2012 · NS · contact PI
DAAO Inhibitors for the treatment of Schizophrenia$593,166
R01 · FY2011 · MH · contact PI
Novel Therapeutic Agents for Gliomas with IDH Mutations$246,000
R21 · FY2011 · NS · contact PI